Irritable bowel syndrome: evaluation and treatment (Q35176961)

6 August 2017

1 reference

title

Irritable bowel syndrome: evaluation and treatment (English)

1 reference

6 August 2017

main subject

irritable bowel syndrome

1 reference

Samuel C Somers

1

1 reference

6 August 2017

Anthony Lembo

series ordinal

2

1 reference

6 August 2017

publication date

1 June 2003

1 reference

Gastroenterology Clinics of North America

6 August 2017

published in

1 reference

6 August 2017

volume

32

1 reference

6 August 2017

issue

2

1 reference

6 August 2017

page(s)

507-529

1 reference

Towards positive diagnosis of the irritable bowel

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(03)50022-0

7 January 2021

Gender differences in Manning criteria in the irritable bowel syndrome.

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(03)50022-0

7 January 2021

Diagnostic value of the Manning criteria in irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(03)50022-0

7 January 2021

Prognosis in the irritable bowel syndrome: a 5-year prospective study

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(03)50022-0

7 January 2021

Irritable Bowel Syndrome–Prognosis and Diagnostic Safety

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(03)50022-0

7 January 2021

Diagnostic criteria for the irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(03)50022-0

7 January 2021

Irritable bowel syndrome according to varying diagnostic criteria: are the new Rome II criteria unnecessarily restrictive for research and practice?

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(03)50022-0

7 January 2021

Irritable bowel syndrome prevalence varies enormously depending on the employed diagnostic criteria: comparison of Rome II versus previous criteria in a general population

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(03)50022-0

7 January 2021

Irritable bowel syndrome in general practice: prevalence, characteristics, and referral

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(03)50022-0

7 January 2021

Irritable bowel syndrome in the general population

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(03)50022-0

7 January 2021

Non-colonic features of irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(03)50022-0

7 January 2021

Irritable bowel syndrome symptom patterns: frequency, duration, and severity

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(03)50022-0

7 January 2021

Level of chronic life stress predicts clinical outcome in irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(03)50022-0

7 January 2021

Irritable bowel syndrome (IBS) and alcohol abuse or dependence

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(03)50022-0

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(03)50022-0

7 January 2021

Bladder smooth muscle dysfunction in patients with irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(03)50022-0

7 January 2021

Severe sexual dysfunction in women with the irritable bowel syndrome: comparison with inflammatory bowel disease and duodenal ulceration

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(03)50022-0

7 January 2021

Primary fibromyalgia and the irritable bowel syndrome: different expressions of a common pathogenetic process

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(03)50022-0

7 January 2021

The menstrual cycle and its effect on inflammatory bowel disease and irritable bowel syndrome: a prevalence study

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(03)50022-0

7 January 2021

More accurate diagnosis of irritable bowel syndrome by the use of 'non-colonic' symptomatology

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(03)50022-0

7 January 2021

Irritable bowel-type symptoms in HMO examinees. Prevalence, demographics, and clinical correlates

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(03)50022-0

7 January 2021

Psychosocial factors are associated with health care seeking rather than diagnosis in irritable bowel syndrome.

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(03)50022-0

7 January 2021

What determines severity among patients with painful functional bowel disorders?

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(03)50022-0

7 January 2021

The irritable bowel syndrome: mechanisms and a practical approach to management

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(03)50022-0

7 January 2021

Irritable bowel syndrome: a technical review for practice guideline development

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(03)50022-0

7 January 2021

Evidence- and consensus-based practice guidelines for the diagnosis of irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(03)50022-0

7 January 2021

Celiac disease and irritable bowel-type symptoms

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(03)50022-0

7 January 2021

AGA technical review on the evaluation and management of chronic diarrhea

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(03)50022-0

7 January 2021

AGA technical review on constipation. American Gastroenterological Association

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(03)50022-0

7 January 2021

Are adverse food reactions linked to irritable bowel syndrome?

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(03)50022-0

7 January 2021

Effects of an irritable bowel syndrome educational class on health-promoting behaviors and symptoms

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(03)50022-0

7 January 2021

Food intolerance: a major factor in the pathogenesis of irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(03)50022-0

7 January 2021

A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(03)50022-0

7 January 2021

Bacterial supplementation in the irritable bowel syndrome. A randomised double-blind placebo-controlled crossover study

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(03)50022-0

7 January 2021

Controlled treatment trials in the irritable bowel syndrome: a critique.

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(03)50022-0

7 January 2021

Treatment of irritable bowel syndrome: a review of randomised controlled trials

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(03)50022-0

7 January 2021

Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(03)50022-0

7 January 2021

Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(03)50022-0

7 January 2021

Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(03)50022-0

7 January 2021

Peppermint oil for irritable bowel syndrome: a critical review and metaanalysis

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(03)50022-0

7 January 2021

Treatment of the irritable bowel syndrome with Bentyl (dicyclomine hydrochloride)

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(03)50022-0

7 January 2021

Treatment of irritable bowel syndrome with lorazepam, hyoscine butylbromide, and ispaghula husk

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(03)50022-0

7 January 2021

A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(03)50022-0

7 January 2021

Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(03)50022-0

7 January 2021

Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(03)50022-0

7 January 2021

A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(03)50022-0

7 January 2021

Pharmacology and clinical experience with alosetron

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(03)50022-0

7 January 2021

Ischemic colitis during treatment with alosetron

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(03)50022-0

7 January 2021

Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(03)50022-0

7 January 2021

An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(03)50022-0

7 January 2021

Review article: tegaserod

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(03)50022-0

7 January 2021

A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(03)50022-0

7 January 2021

Tegaserod, a 5-hydroxytryptamine type 4 receptor partial agonist, is devoid of electrocardiographic effects

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(03)50022-0

7 January 2021

Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(03)50022-0

7 January 2021

The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(03)50022-0

7 January 2021

The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double blind, randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(03)50022-0

7 January 2021

Physiological effects of emotion: assessment via hypnosis

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(03)50022-0

7 January 2021

Changes in rectal sensitivity after hypnotherapy in patients with irritable bowel syndrome.

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(03)50022-0

7 January 2021

Cognitive-Behavioral Group Therapy for Patients with Irritable Bowel Syndrome

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(03)50022-0

7 January 2021

A Randomised Controlled Trial of Psychotherapy in Patients with Refractory Irritable Bowel Syndrome

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(03)50022-0

7 January 2021

Treatment of irritable bowel syndrome with Chinese herbal medicine: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(03)50022-0

7 January 2021

Acupuncture treatment for irritable bowel syndrome. A double-blind controlled study

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(03)50022-0

7 January 2021

Cognitive therapy for irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(03)50022-0

7 January 2021

A controlled comparison of cognitive therapy and self-help support groups in the treatment of irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1016/S0889-8553(03)50022-0

7 January 2021

10.1016/S0889-8553(03)00022-0

Identifiers

DOI

1 reference

6 August 2017

1 reference